Impact of long‐term administration of maralixibat on children with cholestasis secondary to Alagille syndrome

Impact of long‐term administration of maralixibat on children with cholestasis secondary to Alagille syndrome

Abstract There is growing interest in, but limited data about, intestinal bile acid transport inhibitors as treatment for cholestatic liver disease. The current analyses combine two similar randomized placebo‐controlled trials with subsequent extension phases investigating the impact of maralixibat...

Full description

Bibliographic Details
Main Authors: Benjamin L. Shneider, Catherine A. Spino, Binita M. Kamath, John C. Magee, Rosalinda V. Ignacio, Suiyuan Huang, Simon P. Horslen, Jean P. Molleston, Alexander G. Miethke, Rohit Kohli, Daniel H. Leung, M. Kyle Jensen, Kathleen M. Loomes, Saul J. Karpen, Cara Mack, Philip Rosenthal, Robert H. Squires, Alastair Baker, Sanjay Rajwal, Deirdre Kelly, Ronald J. Sokol, Richard J. Thompson, for ChiLDReN and UK IMAGO/IMAGINE Investigators
Format: Article
Language:English
Published: Wolters Kluwer Health/LWW 2022-08-01
Series:Hepatology Communications
Online Access:https://doi.org/10.1002/hep4.1992

Internet

https://doi.org/10.1002/hep4.1992

Similar Items